RxDoctor Payments Data

Brad Manuel, PA

Medical · Burlington, MANPI 1023088697

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.8% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Boston Scientific at 33.9% of the total. Reporting peaked in 2023 at $1,340 and has fallen 67.5% since, to $435 in 2025. Among medical clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,127in general payments, 2019–2025

Across 71 payments — averaging $44.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Abbott$608
  • Relievant Medsystems, Inc.$593
  • Biohaven Pharmaceutical Holding Company Ltd.$244
  • Baudax Bio Inc.$193
  • Medtronic$181
  • plus $247 from 8 others

What the payments were for

  • Travel & lodging$2568%
  • Food & beverage$2,87192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,127 in reported general payments places this provider in the 90th percentile of 421 medical providers in Massachusetts.

See all medical providers in Massachusetts

Medicare billing

Part B allowed, 2024
$63,915
Medicare patients
483
Services billed
1,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate19$34,789
SavellaMilnacipran Hcl17$13,064
Pregabalin342$10,700
Lidocaine26$3,946
Celecoxib39$2,759
Gabapentin273$2,456
Tizanidine Hcl156$1,347
Cyclobenzaprine Hcl152$1,160
Duloxetine Hcl28$1,112
Meloxicam65$326
Baclofen13$261
Lorazepam42$61
Topiramate11$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$48$34,78919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 421 medical providers in Massachusetts.

Other medical in Burlington

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →